Â
MD, DNB Nephrology, FRCP (UK), FASN, FISN, FICP, FIACM, FDI, MNAMS
Associate Professor Nephrology,
VMMC & Safdarjung Hospital,
New Delhi, India
Chair, Dialysis Working Group, ISN
SARB, ISN
Executive Council ISOT
(Click / Tap on Questions to Reveal Content)
No. The term “snakebite AKI” is pathophysiologically reductionist. What we currently classify under a single umbrella actually represents several overlapping renal phenotypes with distinct mechanisms, histology, trajectories, and long-term outcomes-
A. Ischemic acute tubular necrosis (ATN)
Driven by hypotension, vasoplegia, capillary leak, renal vasoconstriction, and microcirculatory collapse. This is probably the commonest phenotype in early shock-mediated injury.
B. Pigment nephropathy
Occurs from: rhabdomyolysis (myoglobin), and intravascular hemolysis (hemoglobin). Your case strongly suggests both- CK 7,500 IU/L, heme-positive urine with few RBCs, and severe hemolysis. Pigment-mediated tubular toxicity synergizes with ischemia rather than acting independently.
C. Venom-induced thrombotic microangiopathy (TMA)
This is increasingly recognized and probably underdiagnosed. The triad thrombocytopenia, MAHA/schistocytes, and AKI, strongly supports TMA in your patient. Indian and Australian cohorts show that TMA is associated with- markedly higher dialysis requirements, prolonged renal recovery, and CKD risk.
D. Renal cortical necrosis
Probably the most devastating phenotype. The mechanisms include endothelial injury, fibrin microthrombi, severe vasospasm, prolonged ischemia, and DIC/VICC overlap. Older Indian biopsy series showed cortical necrosis in nearly one-fourth of severe viper-associated renal failure cases. Many “nonrecovering AKI” survivors likely represent missed cortical necrosis.
E. Direct venom nephrotoxicity
Several venoms exert direct cytotoxic, phospholipase- mediated, endothelial, mitochondrial, and complement- activating injury. The kidney is exposed to extraordinarily high toxin concentrations because of renal blood flow and tubular concentration mechanisms.
So the answer is clear- snakebite AKI is not a single disease. It is a syndrome containing multiple renal endotypes that frequently coexist in the same patient.
Probably not “irrespective of timing.” Timing appears biologically crucial. Antivenom works best before endothelial activation, microvascular thrombosis, established tubular necrosis, cortical ischemia, or pigment-mediated injury have become self-propagating. Once the inflammatory-thrombotic cascade is established, neutralizing circulating venom may not reverse downstream endothelial injury. Evidence suggests that early ASV reduces severity of systemic envenomation. The delays are associated with higher AKI rates and mortality, but robust evidence specifically demonstrating reversal of established TMA or cortical necrosis is lacking. Importantly, ASV neutralizes venom, not host-response biology already triggered by venom. By the time, schistocytes appear, anuria develops, pulmonary edema emerges, or vasopressor needs escalate, the illness may already be partially venom-independent. This distinction is conceptually critical.
This remains biologically attractive but evidence-poor. I would like to give a potential rationale. The circulating venom fragments, inflammatory mediators, endothelial toxins, DAMPs from rhabdomyolysis and hemolysis, or cytokine amplification may contribute to refractory shock and endothelial dysfunction. However, there is currently no high-quality evidence supporting routine hemoadsorption or cytokine adsorption in snakebite envenomation.
Theoretical targets include- CytoSorb-like adsorption, high cutoff membranes, and hemoperfusion strategies. But venom kinetics complicate the issue. Many toxins rapidly redistribute into tissues, and the injury may already be endothelial and microvascular rather than intravascular. Hence, extracorporeal adsorption currently remains mechanistically plausible, experimentally interesting, but clinically unproven. It should not yet be considered standard care.
The evidence is surprisingly weak. This practice is largely extrapolated from crush injury, and rhabdomyolysis literature. Theoretical rationale is that alkaline urine may reduce myoglobin precipitation, heme-protein cast formation, and free radical generation. But controlled evidence demonstrating improved renal outcomes is lacking even in rhabdomyolysis itself. In snakebite specifically, there are no convincing clinical trials proving benefit. Moreover, severe envenomation patients often simultaneously have capillary leak, pulmonary edema, shock, oliguria, and severe endothelial dysfunction, making aggressive bicarbonate infusion physiologically hazardous. Thus, urinary alkalinization remains physiology-driven but evidence-light. Reasonable in selected early rhabdomyolysis with preserved urine flow. Much less convincing in established oligo-anuric multiorgan envenomation.
Increasingly, yes. Your patient illustrates why conventional “AEIOU” triggers are inadequate in toxin-mediated endothelial catastrophes. In severe snakebite, RRT is not merely renal support. It becomes- metabolic stabilization, temperature control, acid-base rescue, cytokine modulation, fluid balance management, and shock facilitation. Waiting for extreme potassium, severe uremia, or refractory acidosis may mean intervening after irreversible microvascular injury is already entrenched. Early extracorporeal support may help avoid fluid overload during resuscitation, control pigment burden, stabilize acidemia, prevent recurrent hyperkalemia, and facilitate lung-protective ventilation. However, we must also be honest. The dialysis does not remove most venom toxins effectively because venom rapidly tissue-binds, many toxins are high molecular weight, and distribution kinetics are unfavorable. Thus, early RRT is probably beneficial for metabolic trajectory control rather than toxin clearance itself.
This is an important and pragmatic question. In many tropical ICUs, SLED may indeed represent the optimal balance between hemodynamic tolerability, cost, nursing burden, anticoagulation avoidance, and machine availability. CRRT is physiologically elegant but, expensive, resource intensive, anticoagulation dependent, and difficult in severe coagulopathy. Snakebite patients frequently have- VICC, thrombocytopenia, bleeding risk,and intermittent hemodynamic fluctuations. SLED offers slower solute shifts, better tolerance than intermittent HD,and less infrastructure burden than CRRT. The preference for CRRT in academic literature partly reflects availability bias, high-income ICU standards, and extrapolation from septic shock literature. There is little high-quality evidence proving CRRT superiority specifically in snakebite AKI. In tropical nephrology practice, SLED is often the most contextually rational modality.
Yes- and this is one of the major conceptual failures in snakebite medicine. Venom-induced consumptive coagulopathy (VICC) consists of prolonged clotting, hypofibrinogenemia, bleeding phenotype, and toxin-mediated coagulation factor consumption. On the other hand, TMA comprises MAHA, schistocytes, thrombocytopenia, organ ischemia, and renal-predominant injury. The two can coexist. Historically, many snakebite patients with thrombocytopenia, AKI, and anemia were simply labeled “DIC” or “coagulopathy.” But modern evidence strongly supports a distinct snakebite-associated TMA phenotype. Failure to recognize TMA matters because it predicts prolonged dialysis dependence, severe AKI, CKD progression, as well as cortical necrosis risk. Your patient almost certainly has overlappingVICC, TMA, pigment nephropathy, and ischemic injury. This overlap is precisely why these cases become biologically chaotic.
Because ICU “survival” is not equivalent to renal recovery. Persistent dialysis dependence likely reflects cortical necrosis, irreversible microvascular dropout, endothelial scarring, maladaptive tubular repair, and nephron loss after TMA. Many patients discharged after “recovery” never undergo MRI, repeat biopsy, structured CKD surveillance, albuminuria assessment, or long-term nephrology follow-up. Consequently, cortical necrosis is probably substantially underrecognized. The kidney may transiently recover enough urine output to create the illusion of recovery while progressive CKD silently evolves. This is especially important in South Asia, where snakebite survivors are young agricultural workers with decades of post-injury life expectancy.
There is also role of TPE (PLEX) in VICC in refractory cases as it is considered some sort of TMA !